Sort
21,453 grants matching “tuberculosis”
Tuberculosis Elimination & Laboratory Cooperative Agreements
$1,227,209James Scioneaux · Louisiana State Office Of Public Health · U52 · FY2013 · PS
Seattle-Lausanne Clinical Trials Unit
$1,226,577Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
FY21 ITCA NARCH XI
$1,226,557Maria Dadgar · Inter Tribal Council Of Arizona, Inc. · S06 · FY2022 · GM
HARLEM AIDS TREATMENT GROUP-'CPCRA'
$1,226,527Columbia University Health Sciences · U01 · FY2002 · AI
Anaerobic shock as a novel treatment for tuberculosis
$1,226,193Xilin Zhao · Rbhs-New Jersey Medical School · DP2 · FY2010 · OD
TUBERCULOSIS ELIMINATION & LABORATORY
$1,226,031Michelle Conner · Georgia Department Of Community Health · U52 · FY2011 · PS
Facility Management, Maintenance and Operation Core
$1,225,794Raymond Paul Goodrich · Colorado State University · UC7 · FY2025 · AI
Impact of tuberculosis on the development and function of the immune system in SIV-infected infants
$1,225,642Xiaolei Wang · Tulane University Of Louisiana · R01 · FY2021 · HD
Impact of tuberculosis on the development and function of the immune system in SIV-infected infants
$1,225,642Xiaolei Wang · Tulane University Of Louisiana · R01 · FY2023 · HD
Impact of tuberculosis on the development and function of the immune system in SIV-infected infants
$1,225,614Xiaolei Wang · Tulane University Of Louisiana · R01 · FY2020 · HD
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)
$1,225,136University Of Alabama At Birmingham · U01 · FY2002 · AI
Vanderbilt HIV Clinical Trials Unit
$1,224,853David W Haas · Vanderbilt University Medical Center · UM1 · FY2016 · AI
Michigan Department of Community Health Tuberculosis Program Tuberculosis Elimination and Laboratory Cooperative Agreement
$1,223,759Jevon McFadden · Michigan State Department Of Health And Human Services · U52 · FY2015 · PS
Innate inflammatory responses during pulmonary infections
$1,222,241Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Developing Teixobactin for Respiratory Infections
$1,221,354Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R01 · FY2024 · AI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
$1,221,014Serena Patricia Koenig · Brigham And Women'S Hospital · U01 · FY2022 · AI
STRUCTURAL BIOLOGY AND TARGETED DRUG DESIGN FOR AIDS
$1,220,651University Of California San Francisco · P01 · FY2001 · GM
Innate inflammatory responses during pulmonary infections
$1,218,475Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Stellenbosch University Clinical Trials Unit
$1,218,433Anneke Catharina Hesseling · Stellenbosch University · UM1 · FY2023 · AI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents
$1,218,191Charles A. Scanga · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · AI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents
$1,216,647Charles A. Scanga · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI
FY21 ITCA NARCH XI
$1,216,518Maria Dadgar · Inter Tribal Council Of Arizona, Inc. · S06 · FY2023 · GM
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit
$1,215,815Pablo Tebas · University Of Pennsylvania · UM1 · FY2017 · AI
India International Center for Excellence in Research
$1,215,718Thomas Nutman · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Chemical Inhibitors to Define an Essential M. Tuberculosis Signaling Network
$1,214,907Robert N Husson · Boston Children'S Hospital · R01 · FY2014 · AI